Britain's National Health Service will make its pioneering Jewish BRCA testing program permanent after a pilot initiative identified hundreds of people carrying inherited cancer-linked genetic mutations, according to a report from The Jewish Chronicle.
The program, launched in partnership with Jewish health organizations and genetic specialists, offers testing for three BRCA mutations that are significantly more prevalent among people of Ashkenazi Jewish ancestry. Carriers face substantially increased risks of developing breast, ovarian, prostate, and pancreatic cancers.
Those with Ashkenazi Jewish ancestry have a one in 40 chance of carrying a BRCA1 or BRCA2 compared to a one in 250 chance for the general population.
“I'm pleased to confirm that BRCA testing for the Jewish community is here to stay, as the NHS plans for this to become routine from 2027/28,” said James Murray, the secretary for health and social care, in an interview with the JC.
Over 700 people have already been identified, giving them access to counseling, monitoring, and in some cases, preventative treatment. This is what our shift from sickness to prevention looks like in practice – catching problems early and giving people the chance to act.”
Success of pilot program led to creation of permanent system
More than 43,000 people registered for testing during the pilot, with over 500 BRCA mutation carriers identified and referred for genetic counseling and preventative care pathways, according to program data.
Louise Hager MBE, chair of Chai Cancer Care, said, “Knowing your genetic risk can be life-changing. Earlier identification of cancer risk gives people the opportunity to make informed decisions about screening, prevention, and treatment, and ultimately can help save lives.”
Many BRCA carriers do not meet traditional family-history criteria for testing despite carrying inherited mutations associated with significantly elevated cancer risks.
NHS officials have indicated that the success of the pilot has helped support plans for a permanent service, with the program expected to inform future approaches to population-based genetic screening and precision medicine.